HOME >> BIOLOGY >> NEWS
AVAX Technologies' M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma

AVAX Technologies, Inc. (NASDAQ: AVXT) today announced the presentation of data at the 91st Annual Meeting of the American Association for Cancer Research (AACR), which indicate that M-Vax™, a cancer vaccine made from the patient's own tumor cells, induces T cell infiltration of metastatic sites. T cells are the class of white blood cells believed to be instrumental in fighting cancer cells. The presentation, entitled "T cell receptor structure of lymphocytes infiltrating melanoma metastases after administration of autologous, dinitrophenyl-modified vaccine," showed data that continue to validate earlier results demonstrating that M-Vax elicits an immune response in patients with advanced disease. Most importantly, the data suggest that the vaccine induces the expansion of novel T cell clones, targeted against the tumor. These T cells are involved in controlling immune reactions and may also be the principal agents of anti-tumor effects. The studies were conducted by David Berd, M.D., inventor of the AC Vaccine™ technology and Professor of Medicine, Thomas Jefferson University.

The data reported represent a follow up of earlier work published in 1997 that demonstrate that certain dominant T cell receptor families were identified in nine out of ten melanoma tumors removed from advanced patients who had an immunologic response to M-Vax. In contrast, examination of control specimens - tumors removed from patients before treatment with M-Vax or T cells extracted from blood showed a random pattern of T cells, which would be expected in the absence of an anti-cancer immune response. These findings suggest that treatment with M-Vax results in the expansion of certain groups of T cells that were not present before treatment, and that these T cells specifically target the tumor.

"In previous studies we found that M-Vax caused the development of inflammation in the tumors," Dr. Berd explained. Dr. Berd said that the tumors bec
'"/>

Contact: Olga Fleming
ofleming@cpronline.com
201-641-2408 ext 34
AVAX Technologies, Inc.
3-Apr-2000


Page: 1 2

Related biology news :

1. Palatin Technologies PT-141 increases sexual behavior in female animals
2. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
3. AVAX Technologies O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer
4. AVAX Technologies AC Vaccine™ improves relapse-free survival
5. Leader in cancer treatment and prevention research honored
6. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
7. Chemical derived from vitamin-E shows early promise as cancer drug
8. New molecular link key to cellular proteins involved in cancer progression, other diseases
9. Phase II trials of second-generation antisense cancer drug planned following successful early study
10. Trial shows which brain cancer patients benefit from temozolomide
11. Genetic differences might help distinguish thyroid cancers

Post Your Comments:
(Date:3/4/2015)... 2015 Research and Markets ( ... "Global Biometrics Market Forecast and Opportunities, 2020" ... market for biometric authentication systems is projected to ... 2020 The driving forces for this ... government projects and constant development in technology. In ...
(Date:3/3/2015)... 3, 2015 Cryoport, Inc. (OTCBB: ... cryogenic logistics solutions for the life sciences ... cell lines, clinical research organizations, vaccine manufacturers, ... the expansion of its relationship with ... Hutch") Clinical Research Division with the inclusion ...
(Date:3/2/2015)... , March 2, 2015 Synaptics Inc. ... of human interface solutions, today announced a new ... designed to enable rapid and secure transactions and ... for gaming is a turnkey solution providing mouse ... to quickly integrate fingerprint ID solutions into their ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
(Date:3/5/2015)... 2015 BioPlus Specialty Pharmacy (BioPlus) announces ... Vice President of Managed Care. In this role, Damm ... of the nation’s leading specialty pharmacies. , Damm, who ... of specialty pharmacy and biotech experience to his new ... Vertex Pharmaceuticals, and Pfizer. Prior to working in Healthcare ...
(Date:3/5/2015)... Bi-Biomics today announced a discovery ... additive. The improvement in histological quality provided the ... in all daughter cells. , After processing with ... analyzed at 1000-1600x using light microscopy. Phylogenetic ... all daughter cells displayed predominant binary features --- ...
(Date:3/5/2015)... Research Triangle Park, NC (PRWEB) March 05, 2015 ... Entegrion, Inc., announced that Pierre Noel, M.D., Professor ... been elected to the Company’s Board of Directors. ... Mowell said, “We are extremely fortunate to have ... with the country’s leading healthcare organization, join Entegrion’s ...
(Date:3/5/2015)... TORONTO , March 5, 2015 /PRNewswire/ - Aptose Biosciences ... new therapeutics and molecular diagnostics that target the underlying ... Rice , Ph.D., Chairman, President and Chief Executive Officer, ... on Tuesday, March 10 th at 9:30 a.m. ... Niguel, CA. Dr. Rice will provide a ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3
Cached News: